Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
July 1, 2010BloodOpen Access

Allogeneic stem cell transplantation provides durable disease control in poor-risk chronic lymphocytic leukemia: long-term clinical and MRD results of the German CLL Study Group CLL3X trial

View Full Paper
Ask AI
Bookmark
Share

Authors

PDPeter DregerHeidelberg University
Hartmut Döhner
Hartmut DöhnerGoethe University FrankfurtMRMatthias RitgenUniversity Hospital Schleswig-Holstein

Discussion

Loading...

Member takes

Implication

Key Points

Key points are not available for this paper at this time.

Cite This Study

Dreger et al. (2010) studied this question.

synapsesocial.com/papers/6a7cd025e4005ef081adc7ffhttps://doi.org/10.1182/blood-2010-03-275420
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1HLA-Identical Sibling Bone Marrow Transplantation in Younger Patients with Chronic Lymphocytic Leukemia1996 · 248 citations
  2. 2HLA-Identical Sibling Compared With 8/8 Matched and Mismatched Unrelated Donor Bone Marrow Transplant for Chronic Phase Chronic Myeloid Leukemia2009 · 110 citations
  3. 3Elevated serum thymidine kinase levels identify a subgroup at high risk of disease progression in early, nonsmoldering chronic lymphocytic leukemia.1999 · 235 citations
  4. 4p53 gene deletion predicts for poor survival and non-response to therapy with purine analogs in chronic B-cell leukemias1995 · 735 citations
  5. 5Graft‐versus‐leukaemia effect after non‐myeloablative haematopoietic transplantation can overcome the unfavourable expression of ZAP‐70 in refractory chronic lymphocytic leukaemia2007 · 95 citations